Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique.
|
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
qdQKZFSsuZmqecXq